AN UMBRELLA REVIEW ON TREATMENTS AND THERAPEUTIC OPTIONS FOR COVID-19 DOI Creative Commons
SeyedAhmad SeyedAlinaghi, Amir Masoud Afsahi, Ayoob Molla

и другие.

Russian Journal of Infection and Immunity, Год журнала: 2023, Номер 13(5), С. 885 - 898

Опубликована: Окт. 20, 2023

Introduction. As the COVID-19 pandemic continues to pose a significant challenge global health, effective therapeutic options for preventing and treating disease have become increasingly important. We aimed provide an update on current treatments patients.Materials methods. The purpose of this umbrella review is explore patients. Keywords their combinations were searched across online databases in Embase, PubMed/MEDLINE, Web Science, Scopus spanning from July 1, 2020, through March 3, 2023. Publications selected data extraction two steps based study inclusion/exclusion criteria. adheres PRISMA checklist as well NIH bias risk quality assessment tool.Results. In review, 28 relevant articles final qualitative synthesis. majority included studies had reported efficacy Lopinavir/Ritonavir (n = 4), Ivermectin 3), Baricitinib 2), Tocilizumab Remdesivir ACEI/ARB Vitamin D Molnupiravir Traditional Chinese medicine (TCM) Convalescent plasma transfusion (CPT) 2) hydroxychloroquine COVID-19. It appeared that Baricitinib, Remdesivir, ACEI/ARB, TCM, CPT may beneficial effects reducing mortality, hospitalization duration, severity Other interventions, such Lopinavir/Ritonavir, Ivermectin, D, Hydroxychloroquine did not show clear benefits or inconclusive results.Conclusion. This provides comprehensive overview evidence effectiveness safety various pharmacological non-pharmacological interventions These results updated landscape treatments, highlighting potential avenues further research clinical practice. crucial continue monitoring emerging conducting rigorous guide development optimization strategies against

Язык: Английский

AN UMBRELLA REVIEW ON TREATMENTS AND THERAPEUTIC OPTIONS FOR COVID-19 DOI Creative Commons
SeyedAhmad SeyedAlinaghi, Amir Masoud Afsahi, Ayoob Molla

и другие.

Russian Journal of Infection and Immunity, Год журнала: 2023, Номер 13(5), С. 885 - 898

Опубликована: Окт. 20, 2023

Introduction. As the COVID-19 pandemic continues to pose a significant challenge global health, effective therapeutic options for preventing and treating disease have become increasingly important. We aimed provide an update on current treatments patients.Materials methods. The purpose of this umbrella review is explore patients. Keywords their combinations were searched across online databases in Embase, PubMed/MEDLINE, Web Science, Scopus spanning from July 1, 2020, through March 3, 2023. Publications selected data extraction two steps based study inclusion/exclusion criteria. adheres PRISMA checklist as well NIH bias risk quality assessment tool.Results. In review, 28 relevant articles final qualitative synthesis. majority included studies had reported efficacy Lopinavir/Ritonavir (n = 4), Ivermectin 3), Baricitinib 2), Tocilizumab Remdesivir ACEI/ARB Vitamin D Molnupiravir Traditional Chinese medicine (TCM) Convalescent plasma transfusion (CPT) 2) hydroxychloroquine COVID-19. It appeared that Baricitinib, Remdesivir, ACEI/ARB, TCM, CPT may beneficial effects reducing mortality, hospitalization duration, severity Other interventions, such Lopinavir/Ritonavir, Ivermectin, D, Hydroxychloroquine did not show clear benefits or inconclusive results.Conclusion. This provides comprehensive overview evidence effectiveness safety various pharmacological non-pharmacological interventions These results updated landscape treatments, highlighting potential avenues further research clinical practice. crucial continue monitoring emerging conducting rigorous guide development optimization strategies against

Язык: Английский

Процитировано

0